ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1651

Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis

Naotake Tsuboi1, Nobuhide Endo1, Seiichi Matsuo2 and Shoichi Maruyama1, 1Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Alternative Activation, biomarkers and lupus nephritis, Macrophage

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: In addition to the effector roles of classically activated macrophages for tissue injury, recent studies have shown that alternatively activated (M2) macrophages are involved in resolution of inflammation in animal models of kidney disease. But, clinical relevance of M2 macrophage in human disease is largely unknown. The current study aimed to evaluate renal accumulation of macrophage phenotypes in human lupus nephritis (LN) and significance of soluble form of CD163 (sCD163), a representative marker for M2 cells, for LN disease activity.

Methods: Plasma, urine and kidney biopsy samples were obtained from 74 patients with LN. Histological features were classified according to the ISN/RPS LN criteria. Immunohistochemical analyses using anti-human CD68, CD163 or CD204 antibodies were performed for identification of macrophage phenotypes. Concentrations sCD163 and MCP-1 in plasma and urine were measured by ELISA.

Results: Immunohistological analysis in LN glomeluli revealed more than 70% of CD68+ macrophages was merged with CD163+ cells and more than 90% of CD163+ cells was merged with CD68+ cells. However, CD163+ cells appeared to be more than CD68+ cells in interstitum, indicating the different origin of glomerular and interstitial CD163+ macophages. The cell counts of glomerular CD68+, CD163+ or CD204+ macrophages were increased in association with severity of biopsy active index (BAI) score in LN. Interstitial CD68+, CD163+ or CD204+macrophage infiltration correlated with eGFR. Urine sCD163 level showed stronger correlation with the number of glomerular CD163 positive cell counts (r=0.501) and BAI score (r=0.644) than plasma sCD163 levels with both of the above (r=0.289 and r=0.295, respectively). Correlation of urine sCD163 with BAI was comparable to that of urine MCP-1 levels (r=0.592) and was much better than NGAL (r=0.174) in LN.

Conclusion: These results suggest that CD163+ or CD204+ macrophage is the dominant phenotype in kidneys of LN patients, and urine sCD163 level has a potential significance for estimation of disease activity in human LN.


Disclosure:

N. Tsuboi,
None;

N. Endo,
None;

S. Matsuo,
None;

S. Maruyama,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-glomerular-macrophage-phenotypes-and-urine-soluble-cd163-with-disease-activity-in-human-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology